{"id":"72caeea6bf1be72f00106000570f5b58fce744233a487b696d2e4c4cb661a5ac","title":"Marginal Revolution: targeted cures create a financing dilemma","argument":"In a post on Marginal Revolution, an unnamed speaker introduces the paper “The Price of a Cure: Luxturna and the Economic Dilemmas of Precision Medicine.” The post challenges the framing of Luxturna’s $850,000 price as private profiteering from publicly funded science. It argues that pharmaceuticals are a hit-driven industry: because most projects fail, successful drugs need to earn more than their direct costs to attract investment across the portfolio. For targeted cures, the post identifies two further pressures. A one-time payment for a cure compresses decades of value into one bill, making financing more of a problem than value. Targeting a drug to a smaller patient group also shrinks its market, which the post says can require higher rewards per patient to sustain incentives to innovate. The paper proposes amortizing payments over time, bundling diagnostics with drugs and insurance, and streamlining regulation to lower development costs. Its stated aim is to preserve innovation while expanding patient access. The post says more such drugs are expected, but gives no implementation details for its proposed toolkit.","topicIds":["power-and-infrastructure","work-and-agency"],"domain":"work","claimType":"attributed reading","limits":"The post does not identify its speaker by name. The post gives no implementation details for the proposed policy toolkit.","speaker":{"name":"Alex Tabarrok","roleAtSource":"Article author"},"source":{"title":"Expensive Pharmaceuticals for Targeted Diseases - Marginal REVOLUTION","publisher":"Marginal Revolution","format":"Article","url":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","publishedAt":"2026-11-02T12:16:34+00:00","dateBasis":"Date stated by the publisher."},"evidence":[{"text":"The post introduces a paper about the economics of pharmaceuticals and targeted drugs that cure.","excerpt":"I discuss the economics of the pharmaceutical industry and the special issues that arise with targeted drugs that cure.","url":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","relationship":"Source-stated"},{"text":"The paper challenges the framing of Luxturna’s $850,000 price as private profiteering from publicly funded science.","excerpt":"The $850,000 price for the gene therapy Luxturna is often framed as a story of private profiteering from publicly funded science. This paper challenges that narrative.","url":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","relationship":"Source-stated"},{"text":"The post argues that failed projects mean successful drugs must earn more than their direct costs to attract investment across a pharmaceutical portfolio.","excerpt":"most projects fail, so the few successes must earn revenues well in excess of their own direct costs if the portfolio as a whole is to attract investment.","url":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","relationship":"Source-stated"},{"text":"The post describes one-time cures as a financing problem because they compress decades of value into a single payment.","excerpt":"the “sticker shock” of one-time cures, which compress decades of value into a single payment, creating a financing problem more than a value problem","url":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","relationship":"Source-stated"},{"text":"The post argues that targeting drugs to smaller patient groups shrinks markets and can require higher rewards per treated patient to maintain incentives to innovate.","excerpt":"precisely targeting drugs to smaller patient groups shrinks the market, requiring higher rewards per treated patient to maintain incentives to innovate.","url":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","relationship":"Source-stated"},{"text":"The paper proposes amortizing payments, bundling diagnostics with drugs and insurance, and streamlining regulation to lower development costs.","excerpt":"amortizing payments over time, bundling diagnostics with drugs and insurance, and streamlining regulation to lower development costs.","url":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","relationship":"Source-stated"}],"sourceMedia":{"status":"not_found","sourceUrl":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","checkedAt":"2026-11-10T10:50:09.937Z","items":[],"note":"No suitable media was found by the supported page extraction."},"assumptions":[],"openQuestion":{"attribution":"Open question","text":"How would the proposed payment, bundling, and regulatory measures work in practice to preserve innovation while expanding patient access?"},"whatWouldChangeView":{"attribution":"Change condition not recorded","text":""},"editorialComparisons":[],"live":{"title":"Marginal Revolution: targeted cures create a financing dilemma","summary":"In a post on Marginal Revolution, an unnamed speaker introduces the paper “The Price of a Cure: Luxturna and the Economic Dilemmas of Precision Medicine.” The post challenges the framing of Luxturna’s $850,000 price as private profiteering from publicly funded science. It argues that pharmaceuticals are a hit-driven industry: because most projects fail, successful drugs need to earn more than their direct costs to attract investment across the portfolio. For targeted cures, the post identifies two further pressures. A one-time payment for a cure compresses decades of value into one bill, making financing more of a problem than value. Targeting a drug to a smaller patient group also shrinks its market, which the post says can require higher rewards per patient to sustain incentives to innovate. The paper proposes amortizing payments over time, bundling diagnostics with drugs and insurance, and streamlining regulation to lower development costs. Its stated aim is to preserve innovation while expanding patient access. The post says more such drugs are expected, but gives no implementation details for its proposed toolkit.","question":"How would the proposed payment, bundling, and regulatory measures work in practice to preserve innovation while expanding patient access?","claims":[{"text":"The post introduces a paper about the economics of pharmaceuticals and targeted drugs that cure.","excerpt":"I discuss the economics of the pharmaceutical industry and the special issues that arise with targeted drugs that cure.","support":"source-stated"},{"text":"The paper challenges the framing of Luxturna’s $850,000 price as private profiteering from publicly funded science.","excerpt":"The $850,000 price for the gene therapy Luxturna is often framed as a story of private profiteering from publicly funded science. This paper challenges that narrative.","support":"source-stated"},{"text":"The post argues that failed projects mean successful drugs must earn more than their direct costs to attract investment across a pharmaceutical portfolio.","excerpt":"most projects fail, so the few successes must earn revenues well in excess of their own direct costs if the portfolio as a whole is to attract investment.","support":"source-stated"},{"text":"The post describes one-time cures as a financing problem because they compress decades of value into a single payment.","excerpt":"the “sticker shock” of one-time cures, which compress decades of value into a single payment, creating a financing problem more than a value problem","support":"source-stated"},{"text":"The post argues that targeting drugs to smaller patient groups shrinks markets and can require higher rewards per treated patient to maintain incentives to innovate.","excerpt":"precisely targeting drugs to smaller patient groups shrinks the market, requiring higher rewards per treated patient to maintain incentives to innovate.","support":"source-stated"},{"text":"The paper proposes amortizing payments, bundling diagnostics with drugs and insurance, and streamlining regulation to lower development costs.","excerpt":"amortizing payments over time, bundling diagnostics with drugs and insurance, and streamlining regulation to lower development costs.","support":"source-stated"}],"limitations":["The post does not identify its speaker by name.","The post gives no implementation details for the proposed policy toolkit."],"mediaId":"f6f12c78bb1e5edeaf57e2af815098112632cc7427ca306202f4993a3415b02a","correctionReason":null,"id":"72caeea6bf1be72f00106000570f5b58fce744233a487b696d2e4c4cb661a5ac","publicationId":"983320f9-f6a4-4eb9-8954-416af82c1e30","version":1,"sourceUrl":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","sourceTitle":"Expensive Pharmaceuticals for Targeted Diseases - Marginal REVOLUTION","publisher":"Marginal Revolution","publishedAt":"2026-11-02T12:16:34+00:00","originalPublished":{"value":"2026-11-02T12:16:34+00:00","precision":"instant","basis":"publisher_page"},"firstObservedAt":"2026-11-02T12:18:56.186Z","createdAt":"2026-11-10T10:34:23.179Z","historical":true,"entityIds":["marginal-revolution"],"topicIds":["power-and-infrastructure","work-and-agency"],"media":[{"id":"f6f12c78bb1e5edeaf57e2af815098112632cc7427ca306202f4993a3415b02a","kind":"article","url":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","sourceUrl":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","label":"Read original","provenance":"source_link","verification":{"status":"verified","checkedAt":"2026-11-03T02:18:03.561Z","method":"acquired_source","contentType":"text/html"},"recommendationReason":"Recommended by Jev for understanding this source; checked by Luna."}],"sourceMedia":{"status":"not_found","sourceUrl":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","checkedAt":"2026-11-10T10:50:09.937Z","items":[],"note":"No suitable media was found by the supported page extraction."},"editorialDecision":{"outcome":"accept","reasonCodes":["useful_perspective"],"rubricVersion":"stream-admission-v5","mediaId":"f6f12c78bb1e5edeaf57e2af815098112632cc7427ca306202f4993a3415b02a","confidence":0.67,"provider":"typesafe","model":"jev-1.13.0","inputHash":"ff6474ef6825760575be8b5e63f7f0d6b22b4c6f2aeaa33cc24241afa8dc0b10","decidedAt":"2026-11-03T02:18:06.129Z","redecided":{"from":"stream-admission-v5","under":"stream-admission-v5+confidence-0.5"}},"provenance":{"textHash":"19f8d383c0db1a39a4fafaa2e16e3689cec188cccacb44ebc7625ae840a451eb","observationId":"503cdde1f482eb763f7d219f9bf82114352a75a50609ebda073404f9551077c8","retrievedAt":"2026-11-03T02:18:03.215Z","kind":"publisher-page","preparer":{"model":"gpt-6-luna","runId":"8f8d9dd0-03e0-4ddd-85c6-00d99b07d051"},"reviewer":{"model":"gpt-6-luna","runId":"32206c61-c92d-4c6f-8707-39485e28a085"}},"audit":{"status":"uncertain","reviewedAt":"2026-11-10T10:34:23.179Z","model":"anthropic/claude-opus-5.5"},"sourceAttribution":{"authors":[{"name":"Alex Tabarrok","url":null,"kind":"unknown"}],"authorRole":"article-author","hosts":[],"status":"stated","authorRoster":{"truncated":false,"omitted":0,"assertionGroupsOmitted":0},"participation":[{"actor":{"name":"Alex Tabarrok","url":null,"kind":"unknown","actorId":null},"role":"author","scope":{"kind":"work-credit","locator":null},"literalCredit":"Alex Tabarrok","status":"stated","provenance":{"basis":"article-jsonld","sourceUrl":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","locator":"document/html[1]/head[0]/script[53]@2226.@graph[0].author"},"assertionId":"f2c0847af77e2fe7818bdedc33a46a294d87b4b4082f726329806fcfb4896bc3:participation:0","identity":{"version":"entity-identity-v1","status":"unresolved","actorId":null,"canonicalActorId":null,"candidateActorIds":[],"assertions":[],"sourceObservedAt":"2026-11-10T10:50:09.937Z","knowledgeAsOf":null},"sourceVersion":{"snapshotId":"f2c0847af77e2fe7818bdedc33a46a294d87b4b4082f726329806fcfb4896bc3","sourceUrl":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","contentSha256":"14bd1819e996bd95c21efb24a240b4babd5af8e8e925c196b04f168839d3c108","textHash":"19f8d383c0db1a39a4fafaa2e16e3689cec188cccacb44ebc7625ae840a451eb","observedAt":"2026-11-10T10:50:09.937Z"}}],"participationCoverage":{"total":2,"returned":1,"complete":false,"fullAssertions":"source-metadata-endpoint"},"distribution":null,"publisher":null,"sourceUrl":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","snapshotId":"f2c0847af77e2fe7818bdedc33a46a294d87b4b4082f726329806fcfb4896bc3","contentSha256":"14bd1819e996bd95c21efb24a240b4babd5af8e8e925c196b04f168839d3c108","textHash":"19f8d383c0db1a39a4fafaa2e16e3689cec188cccacb44ebc7625ae840a451eb","observedAt":"2026-11-10T10:50:09.937Z","basis":"publisher-page-metadata","sourceLinks":1,"linksTruncated":false,"metadataUrl":"/api/pipeline/stream/72caeea6bf1be72f00106000570f5b58fce744233a487b696d2e4c4cb661a5ac/source"}},"canonicalUrl":"https://escapemeridian.com/readings/marginal-revolution-targeted-cures-create-a-financing-dilemma-72caeea6","formats":{"html":"/readings/marginal-revolution-targeted-cures-create-a-financing-dilemma-72caeea6","markdown":"/readings/marginal-revolution-targeted-cures-create-a-financing-dilemma-72caeea6.md","json":"/readings/marginal-revolution-targeted-cures-create-a-financing-dilemma-72caeea6.json"},"attribution":"Headline and summary by Escape Meridian, prepared by Luna from the attributed source. A source check is not independent confirmation of the source’s claims.","maintainedGuideLinks":[],"readerContext":{"version":"reader-context-v1","attribution":"Reference context selected by Escape Meridian; separate from source evidence. Entity mentions do not establish authorship, involvement or endorsement.","terms":[],"entities":[{"id":"marginal-revolution","name":"Marginal Revolution","kind":"organization","context":"Economics publication by Tyler Cowen and Alex Tabarrok.","referenceUrls":["https://marginalrevolution.com/"],"path":"/entities/marginal-revolution","json":"/entities/marginal-revolution.json","markdown":"/entities/marginal-revolution.md"},{"id":"time","name":"TIME","kind":"organization","context":"TIME is a news magazine publishing reporting on world affairs, business, technology and the workers behind digital services.","referenceUrls":["https://time.com/"],"path":"/entities/time","json":"/entities/time.json","markdown":"/entities/time.md"}]},"researchQuestions":[],"withdrawn":false,"references":{"schemaVersion":1,"target":{"type":"reading","id":"72caeea6bf1be72f00106000570f5b58fce744233a487b696d2e4c4cb661a5ac","revision":"983320f9-f6a4-4eb9-8954-416af82c1e30","revisionKind":"publication-id","title":"Marginal Revolution: targeted cures create a financing dilemma","url":"https://escapemeridian.com/readings/marginal-revolution-targeted-cures-create-a-financing-dilemma-72caeea6"},"source":{"type":"source","id":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","revision":"19f8d383c0db1a39a4fafaa2e16e3689cec188cccacb44ebc7625ae840a451eb","revisionKind":"sha256-source-text","title":"Expensive Pharmaceuticals for Targeted Diseases - Marginal REVOLUTION","url":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html"},"status":"available","items":[],"next":null,"scope":"Explicit citations in public readings and public file attachments to this reading. Shared topics are not citations. Other artifact types need an explicit reference adapter."},"revisions":[{"id":"72caeea6bf1be72f00106000570f5b58fce744233a487b696d2e4c4cb661a5ac","title":"Marginal Revolution: targeted cures create a financing dilemma","argument":"In a post on Marginal Revolution, an unnamed speaker introduces the paper “The Price of a Cure: Luxturna and the Economic Dilemmas of Precision Medicine.” The post challenges the framing of Luxturna’s $850,000 price as private profiteering from publicly funded science. It argues that pharmaceuticals are a hit-driven industry: because most projects fail, successful drugs need to earn more than their direct costs to attract investment across the portfolio. For targeted cures, the post identifies two further pressures. A one-time payment for a cure compresses decades of value into one bill, making financing more of a problem than value. Targeting a drug to a smaller patient group also shrinks its market, which the post says can require higher rewards per patient to sustain incentives to innovate. The paper proposes amortizing payments over time, bundling diagnostics with drugs and insurance, and streamlining regulation to lower development costs. Its stated aim is to preserve innovation while expanding patient access. The post says more such drugs are expected, but gives no implementation details for its proposed toolkit.","topicIds":["power-and-infrastructure","work-and-agency"],"domain":"work","claimType":"attributed reading","limits":"The post does not identify its speaker by name. The post gives no implementation details for the proposed policy toolkit.","speaker":{"name":"Alex Tabarrok","roleAtSource":"Article author"},"source":{"title":"Expensive Pharmaceuticals for Targeted Diseases - Marginal REVOLUTION","publisher":"Marginal Revolution","format":"Article","url":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","publishedAt":"2026-11-02T12:16:34+00:00","dateBasis":"Date stated by the publisher."},"evidence":[{"text":"The post introduces a paper about the economics of pharmaceuticals and targeted drugs that cure.","excerpt":"I discuss the economics of the pharmaceutical industry and the special issues that arise with targeted drugs that cure.","url":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","relationship":"Source-stated"},{"text":"The paper challenges the framing of Luxturna’s $850,000 price as private profiteering from publicly funded science.","excerpt":"The $850,000 price for the gene therapy Luxturna is often framed as a story of private profiteering from publicly funded science. This paper challenges that narrative.","url":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","relationship":"Source-stated"},{"text":"The post argues that failed projects mean successful drugs must earn more than their direct costs to attract investment across a pharmaceutical portfolio.","excerpt":"most projects fail, so the few successes must earn revenues well in excess of their own direct costs if the portfolio as a whole is to attract investment.","url":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","relationship":"Source-stated"},{"text":"The post describes one-time cures as a financing problem because they compress decades of value into a single payment.","excerpt":"the “sticker shock” of one-time cures, which compress decades of value into a single payment, creating a financing problem more than a value problem","url":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","relationship":"Source-stated"},{"text":"The post argues that targeting drugs to smaller patient groups shrinks markets and can require higher rewards per treated patient to maintain incentives to innovate.","excerpt":"precisely targeting drugs to smaller patient groups shrinks the market, requiring higher rewards per treated patient to maintain incentives to innovate.","url":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","relationship":"Source-stated"},{"text":"The paper proposes amortizing payments, bundling diagnostics with drugs and insurance, and streamlining regulation to lower development costs.","excerpt":"amortizing payments over time, bundling diagnostics with drugs and insurance, and streamlining regulation to lower development costs.","url":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","relationship":"Source-stated"}],"sourceMedia":{"status":"not_found","sourceUrl":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","checkedAt":"2026-11-10T10:50:09.937Z","items":[],"note":"No suitable media was found by the supported page extraction."},"assumptions":[],"openQuestion":{"attribution":"Open question","text":"How would the proposed payment, bundling, and regulatory measures work in practice to preserve innovation while expanding patient access?"},"whatWouldChangeView":{"attribution":"Change condition not recorded","text":""},"editorialComparisons":[],"live":{"title":"Marginal Revolution: targeted cures create a financing dilemma","summary":"In a post on Marginal Revolution, an unnamed speaker introduces the paper “The Price of a Cure: Luxturna and the Economic Dilemmas of Precision Medicine.” The post challenges the framing of Luxturna’s $850,000 price as private profiteering from publicly funded science. It argues that pharmaceuticals are a hit-driven industry: because most projects fail, successful drugs need to earn more than their direct costs to attract investment across the portfolio. For targeted cures, the post identifies two further pressures. A one-time payment for a cure compresses decades of value into one bill, making financing more of a problem than value. Targeting a drug to a smaller patient group also shrinks its market, which the post says can require higher rewards per patient to sustain incentives to innovate. The paper proposes amortizing payments over time, bundling diagnostics with drugs and insurance, and streamlining regulation to lower development costs. Its stated aim is to preserve innovation while expanding patient access. The post says more such drugs are expected, but gives no implementation details for its proposed toolkit.","question":"How would the proposed payment, bundling, and regulatory measures work in practice to preserve innovation while expanding patient access?","claims":[{"text":"The post introduces a paper about the economics of pharmaceuticals and targeted drugs that cure.","excerpt":"I discuss the economics of the pharmaceutical industry and the special issues that arise with targeted drugs that cure.","support":"source-stated"},{"text":"The paper challenges the framing of Luxturna’s $850,000 price as private profiteering from publicly funded science.","excerpt":"The $850,000 price for the gene therapy Luxturna is often framed as a story of private profiteering from publicly funded science. This paper challenges that narrative.","support":"source-stated"},{"text":"The post argues that failed projects mean successful drugs must earn more than their direct costs to attract investment across a pharmaceutical portfolio.","excerpt":"most projects fail, so the few successes must earn revenues well in excess of their own direct costs if the portfolio as a whole is to attract investment.","support":"source-stated"},{"text":"The post describes one-time cures as a financing problem because they compress decades of value into a single payment.","excerpt":"the “sticker shock” of one-time cures, which compress decades of value into a single payment, creating a financing problem more than a value problem","support":"source-stated"},{"text":"The post argues that targeting drugs to smaller patient groups shrinks markets and can require higher rewards per treated patient to maintain incentives to innovate.","excerpt":"precisely targeting drugs to smaller patient groups shrinks the market, requiring higher rewards per treated patient to maintain incentives to innovate.","support":"source-stated"},{"text":"The paper proposes amortizing payments, bundling diagnostics with drugs and insurance, and streamlining regulation to lower development costs.","excerpt":"amortizing payments over time, bundling diagnostics with drugs and insurance, and streamlining regulation to lower development costs.","support":"source-stated"}],"limitations":["The post does not identify its speaker by name.","The post gives no implementation details for the proposed policy toolkit."],"mediaId":"f6f12c78bb1e5edeaf57e2af815098112632cc7427ca306202f4993a3415b02a","correctionReason":null,"id":"72caeea6bf1be72f00106000570f5b58fce744233a487b696d2e4c4cb661a5ac","publicationId":"983320f9-f6a4-4eb9-8954-416af82c1e30","version":1,"sourceUrl":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","sourceTitle":"Expensive Pharmaceuticals for Targeted Diseases - Marginal REVOLUTION","publisher":"Marginal Revolution","publishedAt":"2026-11-02T12:16:34+00:00","originalPublished":{"value":"2026-11-02T12:16:34+00:00","precision":"instant","basis":"publisher_page"},"firstObservedAt":"2026-11-02T12:18:56.186Z","createdAt":"2026-11-10T10:34:23.179Z","historical":true,"entityIds":["marginal-revolution"],"topicIds":["power-and-infrastructure","work-and-agency"],"media":[{"id":"f6f12c78bb1e5edeaf57e2af815098112632cc7427ca306202f4993a3415b02a","kind":"article","url":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","sourceUrl":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","label":"Read original","provenance":"source_link","verification":{"status":"verified","checkedAt":"2026-11-03T02:18:03.561Z","method":"acquired_source","contentType":"text/html"},"recommendationReason":"Recommended by Jev for understanding this source; checked by Luna."}],"sourceMedia":{"status":"not_found","sourceUrl":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","checkedAt":"2026-11-10T10:50:09.937Z","items":[],"note":"No suitable media was found by the supported page extraction."},"editorialDecision":{"outcome":"accept","reasonCodes":["useful_perspective"],"rubricVersion":"stream-admission-v5","mediaId":"f6f12c78bb1e5edeaf57e2af815098112632cc7427ca306202f4993a3415b02a","confidence":0.67,"provider":"typesafe","model":"jev-1.13.0","inputHash":"ff6474ef6825760575be8b5e63f7f0d6b22b4c6f2aeaa33cc24241afa8dc0b10","decidedAt":"2026-11-03T02:18:06.129Z","redecided":{"from":"stream-admission-v5","under":"stream-admission-v5+confidence-0.5"}},"provenance":{"textHash":"19f8d383c0db1a39a4fafaa2e16e3689cec188cccacb44ebc7625ae840a451eb","observationId":"503cdde1f482eb763f7d219f9bf82114352a75a50609ebda073404f9551077c8","retrievedAt":"2026-11-03T02:18:03.215Z","kind":"publisher-page","preparer":{"model":"gpt-6-luna","runId":"8f8d9dd0-03e0-4ddd-85c6-00d99b07d051"},"reviewer":{"model":"gpt-6-luna","runId":"32206c61-c92d-4c6f-8707-39485e28a085"}},"audit":{"status":"uncertain","reviewedAt":"2026-11-10T10:34:23.179Z","model":"anthropic/claude-opus-5.5"},"sourceAttribution":{"authors":[{"name":"Alex Tabarrok","url":null,"kind":"unknown"}],"authorRole":"article-author","hosts":[],"status":"stated","authorRoster":{"truncated":false,"omitted":0,"assertionGroupsOmitted":0},"participation":[{"actor":{"name":"Alex Tabarrok","url":null,"kind":"unknown","actorId":null},"role":"author","scope":{"kind":"work-credit","locator":null},"literalCredit":"Alex Tabarrok","status":"stated","provenance":{"basis":"article-jsonld","sourceUrl":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","locator":"document/html[1]/head[0]/script[53]@2226.@graph[0].author"},"assertionId":"f2c0847af77e2fe7818bdedc33a46a294d87b4b4082f726329806fcfb4896bc3:participation:0","identity":{"version":"entity-identity-v1","status":"unresolved","actorId":null,"canonicalActorId":null,"candidateActorIds":[],"assertions":[],"sourceObservedAt":"2026-11-10T10:50:09.937Z","knowledgeAsOf":null},"sourceVersion":{"snapshotId":"f2c0847af77e2fe7818bdedc33a46a294d87b4b4082f726329806fcfb4896bc3","sourceUrl":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","contentSha256":"14bd1819e996bd95c21efb24a240b4babd5af8e8e925c196b04f168839d3c108","textHash":"19f8d383c0db1a39a4fafaa2e16e3689cec188cccacb44ebc7625ae840a451eb","observedAt":"2026-11-10T10:50:09.937Z"}}],"participationCoverage":{"total":2,"returned":1,"complete":false,"fullAssertions":"source-metadata-endpoint"},"distribution":null,"publisher":null,"sourceUrl":"https://marginalrevolution.com/marginalrevolution/2026/11/expensive-pharmaceuticals-for-targeted-diseases.html","snapshotId":"f2c0847af77e2fe7818bdedc33a46a294d87b4b4082f726329806fcfb4896bc3","contentSha256":"14bd1819e996bd95c21efb24a240b4babd5af8e8e925c196b04f168839d3c108","textHash":"19f8d383c0db1a39a4fafaa2e16e3689cec188cccacb44ebc7625ae840a451eb","observedAt":"2026-11-10T10:50:09.937Z","basis":"publisher-page-metadata","sourceLinks":1,"linksTruncated":false,"metadataUrl":"/api/pipeline/stream/72caeea6bf1be72f00106000570f5b58fce744233a487b696d2e4c4cb661a5ac/source"}}}],"audits":[{"publicationId":"983320f9-f6a4-4eb9-8954-416af82c1e30","verdict":"uncertain","findings":[{"dimension":"attribution","status":"uncertain","explanation":"The draft calls the writer an 'unnamed speaker' who 'introduces the paper,' but the post describes it as the author's own work. The evidence does not name the author, so the identity remains unclear. The reading also obscures that the poster is presenting their own argument, not reviewing someone else's. Smallest repair: say the post's unnamed author presents their own paper, published in the Journal of Law, Medicine and Ethics.","excerpt":"My latest paper, The Price of a Cure: Luxturna and the Economic Dilemmas of Precision Medicine, is in the Journal of Law, Medicine and Ethics."},{"dimension":"summary","status":"uncertain","explanation":"The argument is faithfully conveyed, but the central term Luxturna is never identified as a gene therapy. Precision medicine and targeted drugs also go unexplained, so a general reader may not know what is being priced. The title merges two distinct challenges into a 'financing dilemma'; the source labels only the sticker-shock issue as a financing problem. The question is reasonable. Smallest repair: identify Luxturna as a gene therapy and briefly explain precision medicine as drugs aimed at narrow patient groups.","excerpt":"The $850,000 price for the gene therapy Luxturna is often framed as a story of private profiteering from publicly funded science."},{"dimension":"date","status":"pass","explanation":"originalPublished (2026-11-02T12:16:34Z, publisher page) matches the feed entry and is consistent with first observation shortly afterward. No earlier publication is indicated.","excerpt":null},{"dimension":"support","status":"pass","explanation":"Each claim closely tracks the source's wording and is framed as the post's or paper's argument. Hedging such as 'can require' slightly softens 'requiring' but does not misrepresent it. The limitation about missing implementation details accurately reflects the post. No unsupported benefits or costs are introduced.","excerpt":"Rather than simply controlling prices, the paper proposes a policy toolkit that includes amortizing payments over time, bundling diagnostics with drugs and insurance, and streamlining regulation to lower development costs."},{"dimension":"media","status":"pass","explanation":"The selected media is the verified direct link to the original Marginal Revolution post, which is the source itself.","excerpt":null}],"createdAt":"2026-11-10T10:34:23.179Z","model":"anthropic/claude-opus-5.5"}],"correctionUrl":"https://escapemeridian.com/corrections/"}